Tarsus Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Published on February 25, 2026
IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company focused on therapeutic eyecare, announced positive financial results for the fourth quarter and full-year ending December 31, 2025, primarily driven by the successful commercial launch of its Demodex blepharitis eye drop, Xdemvy. The company reported full-year net product sales for 2025 of $451.4 million, an increase from $180.1 million in 2024, alongside fourth-quarter net sales that grew to $151.7 million compared with $66.4 million in the prior-year period.
Continue reading on website
Other news

Meta-Analysis Finds Weakness in Statistical Robustness of MIGS Studies

February 25, 2026
Understanding whether statistically significant results are robust or “fragile” in MIGS trials has important implications. Clinicians interpreting trial data may overestimate treatment effectiveness if apparent significance relies on only a few participants’ outcomes. Regulatory authorities and guideline committees might also benefit from recognizing fragility as a measure of evidence strength whe

Optical Women’s Association to Host OWA Global Event at 100% Optical

February 25, 2026
LONDON—The Optical Women’s Association (OWA) has announced that it is expanding its international reach with a dedicated OWA Global Event at 100% Optical, the U.K.’s leading annual event for optical professionals, set to take place here February 28 through March 2. The OWA’s international expansion initiatives aim to create even more opportunities for women across the optical industry to connect,